platinum has been researched along with maytansine in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (75.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
Authors | Studies |
---|---|
Ab, O; Bartle, LM; Coccia, J; Lanieri, L; Lee, J; Pinkas, J; Ponte, JF; Ruiz-Soto, R; Themeles, M; Zhou, Y | 1 |
Birrer, MJ; Konner, JA; Martin, LP; Matulonis, UA; Moore, KN; O'Malley, DM; Ponte, JF; Vergote, I | 1 |
Banerjee, S; Birrer, MJ; Colombo, N; Malek, K; Moore, KN; Oaknin, A; Oza, A; Pautier, P; Vergote, I | 1 |
Park, JY; Park, SG; Seo, MD; Sim, YH; Um, YJ | 1 |
1 review(s) available for platinum and maytansine
Article | Year |
---|---|
A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.
Topics: Antibodies, Monoclonal, Humanized; Drug Resistance, Neoplasm; Female; Folate Receptor 1; Humans; Immunoconjugates; Maytansine; Ovarian Neoplasms; Platinum | 2018 |
1 trial(s) available for platinum and maytansine
Article | Year |
---|---|
FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Immunoconjugates; Maytansine; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Prognosis; Survival Rate | 2018 |
2 other study(ies) available for platinum and maytansine
Article | Year |
---|---|
Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carboplatin; Cell Cycle; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Female; Folate Receptor 1; Humans; Immunoconjugates; Maytansine; Mice; Neovascularization, Pathologic; Ovarian Neoplasms; Platinum; Xenograft Model Antitumor Assays | 2016 |
A Novel Antibody-Drug Conjugate Targeting Nectin-2 Suppresses Ovarian Cancer Progression in Mouse Xenograft Models.
Topics: Animals; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Female; Heterografts; Humans; Immunoconjugates; Immunoglobulin G; Maytansine; Mice; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Xenograft Model Antitumor Assays | 2022 |